Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells
About:Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells - cryopreserved BMMCs isolated from clinically confirmed MDS donors. MDS diagnosis requires marrow evaluation of dysplasia and blast percentage, information peripheral blood cannot provide. Ideal for cytogenetic and IPSS-R risk stratification studies. Stratification by blast percentage, cytogenetic risk group, and treatment history.
About Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells
Myelodysplastic Syndrome (MDS) Bone Marrow Mononuclear Cells for Hematology Research
Myelodysplastic syndrome (MDS) bone marrow mononuclear cells (BMMCs) are isolated by density-gradient separation from bone marrow aspirate, capturing the full spectrum of marrow-resident hematopoietic stem, progenitor, and precursor cells that peripheral blood samples do not contain. Samples come from consented donors under IRB-approved protocols, each clinically diagnosed with MDS — a clonal hematopoietic stem cell disorder characterized by ineffective hematopoiesis.
MDS Biology and Why Bone Marrow
- MDS is defined by dysplastic changes across one or more hematopoietic lineages and by marrow blast percentage, both of which require direct marrow evaluation and cannot be assessed from peripheral blood alone.
- Cytogenetic abnormalities, assessed on marrow aspirate, are incorporated into the Revised International Prognostic Scoring System (IPSS-R), the standard tool for risk stratification and treatment planning.
- Marrow blast percentage determines classification and monitors progression risk toward acute myeloid leukemia, a transformation that occurs in a meaningful subset of MDS cases.
- Hypomethylating agents and, in eligible patients, stem cell transplantation are guided by marrow-based risk assessment, making marrow material central to treatment-response research.
- Clonal hematopoiesis and somatic mutation studies (including SF3B1, TET2, and ASXL1) rely on marrow-derived material to characterize disease biology and clonal evolution.
Donor Stratification Available
- IPSS-R risk category where documented
- Marrow blast percentage at collection
- Cytogenetic abnormalities and somatic mutation status where documented
- Treatment history, including hypomethylating agents or transplant
- Age band and sex assigned at birth
- Matched healthy bone marrow controls available
Product Features
- Isolated from clinically confirmed MDS donor bone marrow aspirate
- Density-gradient purified and cryopreserved
- Research Use Only (RUO)
- IRB-approved protocols with documented consent
- Standard and custom cell quantities available
De-identified Donor Data
- MDS diagnosis confirmation and IPSS-R risk category where documented
- Age, sex assigned at birth, and ethnicity
- Donor-reported allergy and infectious disease history
- Treatment history where documented
- Additional MDS-specific metadata available on request
Applications
- Cytogenetic and IPSS-R risk stratification studies
- Somatic mutation and clonal hematopoiesis research (SF3B1, TET2, ASXL1)
- Progression-to-AML biomarker studies
- Hypomethylating agent pharmacodynamic research
- Dysplasia and ineffective hematopoiesis mechanism studies
Other Specimen Types
For matched marrow-derived material across conditions, see our human bone marrow mononuclear cells collection.
Compliance and Quality Assurance
- IRB-approved and HIPAA-compliant protocols
- Electronic informed consent with 21 CFR Part 11-compliant e-signatures
- Documentation support available for regulatory review
Ordering & Customization
MDS BMMCs are available in standard and custom cell quantities. For pricing, international orders, or documentation requirements, please contact our team to confirm compatibility with your country’s regulations.
Donor Metadata
- Verified diagnosis and clinical history
- Demographic data: age, sex assigned at birth, race/ethnicity
- Medication and treatment background when available
Compliance and Quality Assurance
- IRB-approved collections and standardized procedures
- 21 CFR Part 11-compliant e-consent system
- HIPAA-compliant data management
Ordering & Customization
Human Bone Marrow Mononuclear Cells are available in customizable aliquot sizes. For international orders or documentation needs, please contact learnmore@sanguinebio.com to confirm requirements and availability. We also work with multiple ordering platforms and distributors, learn more here.
Protocols & Documentation
-
Informed Consent Form (ICF)
Available upon request — confirms donor consent for research use and downstream commercialization.
Where can I find your complete catalog?
You can find our full product catalog here.
How long can samples be stored?
Storage depends on sample type but often cryopreserved samples stored in liquid nitrogen can be stored for years.
What customization options are available?
Extensive customization is available. To discuss your project request a quote or email us at learnmore@sanguinebio.com.
Do you offer prospective collections?
Sanguine offers flexible prospective collection services tailored to fit your research. For more information and to request a quote, please see: our prospective biospecimen collection services page.
What is the turnaround time for custom collections?
Timelines depend on condition, sample type, and I/E criteria but we often start collection within 2 weeks of signed agreement.
Do you have samples in stock?
YES - we have in-stock inventory. You can also email us at learnmore@sanguinebio.com as we continually get new samples in our inventory.
What does unique donor mean?
Each sample from a different individual - Unique donor means each sample comes from a different person, ensuring biological diversity in your study.
Are samples collected under IRB-approved protocols?
YES - "IRB-approved collection protocols" and IRB approval documentation available upon request. Sanguine utilizes two internationally-recognized IRBs (Advarra and WCG IRB) for review and approval.
Frequently Asked Questions
Ask a Question
Need a custom Bone Marrow Mononuclear Cells cohort?
Our scientific team can scope prospective collections with donor-specific I/E criteria, typically starting within 2 weeks of agreement.